| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/22/2010 | WO2009121845A3 Method to design and uses of overlapping peptides for monitoring t-cell responses in hiv patients |
| 04/22/2010 | WO2009120905A3 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 04/22/2010 | WO2009117289A3 Methods for treating psoriasis |
| 04/22/2010 | WO2009114533A3 Modulation of blood brain barrier permeability |
| 04/22/2010 | WO2009114485A3 Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
| 04/22/2010 | WO2009101208A3 Immunotherapy targeting intracellular pathogens |
| 04/22/2010 | WO2008121329A3 Turkey herpesvirus vectored recombinant containing avian influenza genes |
| 04/22/2010 | US20100100979 Biomarker specific for cancer |
| 04/22/2010 | US20100099854 Neurovirulent strain of the west nile virus and uses thereof |
| 04/22/2010 | US20100099853 Multivalent Antibody Constructs |
| 04/22/2010 | US20100099742 Sensitizing Cells for Apoptosis by Selectively Blocking Cytokines |
| 04/22/2010 | US20100099613 Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| 04/22/2010 | US20100099111 Antibodies against a protein entitled 161p2f10b |
| 04/22/2010 | US20100098772 Drug delivery systems and methods for treating neovascularization |
| 04/22/2010 | US20100098730 Immunoglobulin variants and uses thereof |
| 04/22/2010 | US20100098729 Novel surface exposed immunoglobulin d-binding protein from foraxella catarrhalis |
| 04/22/2010 | US20100098728 Immunostimulating composition containing Lactic Acid bacteria |
| 04/22/2010 | US20100098727 Methods for treating eye disorders |
| 04/22/2010 | US20100098726 Virus-expressing host costimulation molecules |
| 04/22/2010 | US20100098725 Methods for cultivating cells, propagating and purifying viruses |
| 04/22/2010 | US20100098724 Immunoenhacer-linked oligomeric hiv vaccines |
| 04/22/2010 | US20100098723 Vaccine compositions against infectious pathologies for mammals |
| 04/22/2010 | US20100098722 Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use |
| 04/22/2010 | US20100098721 Methods and compositions for preparing a universal influenza vaccine |
| 04/22/2010 | US20100098719 Fusion Proteins Comprising Two or More IgG Binding Domains of Streptococcal Protein G |
| 04/22/2010 | US20100098718 Nucleic acid vectors for immunization |
| 04/22/2010 | US20100098717 Polypeptides Recognized by Anti-Trichinella Antibodies, and Uses Thereof |
| 04/22/2010 | US20100098716 Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| 04/22/2010 | US20100098715 Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders |
| 04/22/2010 | US20100098714 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| 04/22/2010 | US20100098713 Drug screening; assay for aldehyde dehydrogenase activity; cancer |
| 04/22/2010 | US20100098712 Pharmaceutical formulation of an antibody against OX40L |
| 04/22/2010 | US20100098711 Antagonist antibodies against ephb3 |
| 04/22/2010 | US20100098710 Anti-IGF-1R Antibodies and Uses Thereof |
| 04/22/2010 | US20100098709 Antibodies Specific For The Complex Of Interleukin-6 And The Interleukin-6 Receptor |
| 04/22/2010 | US20100098708 Methods of preventing and treating rsv infections and related conditions |
| 04/22/2010 | US20100098707 amyloidosis; neurological disorders such as Alzheimer's Disease |
| 04/22/2010 | US20100098706 Monoclonal antibody directed against the human ldl receptor |
| 04/22/2010 | US20100098705 Method and tool for predicting cancer and other diseases |
| 04/22/2010 | US20100098704 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| 04/22/2010 | US20100098703 Determination of am-binding proteins and the association of adrenomedullin (am) therewith |
| 04/22/2010 | US20100098702 Method of treating androgen independent prostate cancer |
| 04/22/2010 | US20100098701 Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| 04/22/2010 | US20100098700 Pharmaceutical compositions for binding sphingosine-1-phosphate |
| 04/22/2010 | US20100098699 Methods of using LRR superfamily genes and proteins |
| 04/22/2010 | US20100098698 Targeted apheresis for the treatment of rheumatoid arthritis |
| 04/22/2010 | US20100098697 Chlamydia trachomatis antigens |
| 04/22/2010 | US20100098696 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
| 04/22/2010 | US20100098695 Biomarker specific to brain/nerve or specific to neuronal differentiation |
| 04/22/2010 | US20100098694 Antibodies to cd40 |
| 04/22/2010 | US20100098693 Compositions and methods for blood-brain barrier delivery of organophosphatases |
| 04/22/2010 | US20100098692 Humanized Endoglin Antibodies |
| 04/22/2010 | US20100098691 Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| 04/22/2010 | US20100098690 Pharmaceutical composition |
| 04/22/2010 | US20100098689 4-1 bb ligand in inflammatory diseases |
| 04/22/2010 | US20100098688 Method for diagnosis of a disease involving an anti-at1-receptor antibody |
| 04/22/2010 | US20100098687 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| 04/22/2010 | US20100098686 Method for reducing levels of C-reactive protein |
| 04/22/2010 | US20100098685 Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto |
| 04/22/2010 | US20100098684 Biomarkers and methods for detecting and treating spinal and joint pain |
| 04/22/2010 | US20100098683 MUC1 and Galectin-3 |
| 04/22/2010 | US20100098661 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| 04/22/2010 | US20100098659 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| 04/22/2010 | US20100098657 Method of Treating Cancer with Immunomodulatory Compounds and IgG |
| 04/22/2010 | US20100098638 RIP140 Regulation of Diabetes |
| 04/22/2010 | US20100098635 Modular antigen transporter molecules (mat molecules) for modulating immune reactions, associated constructs, methods and uses |
| 04/22/2010 | US20100098628 Proteins |
| 04/22/2010 | US20100098627 Proteins |
| 04/22/2010 | US20100098626 Protein |
| 04/22/2010 | US20100098624 Method for using cdo antagonists to modulate hedgehog signaling |
| 04/22/2010 | US20100096287 Immune Response Modifier Compositions and Methods |
| 04/22/2010 | CA2740871A1 Biomarkers and methods for detecting and treating spinal and joint pain |
| 04/22/2010 | CA2740779A1 Tumor vaccine |
| 04/22/2010 | CA2740716A1 Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc) |
| 04/22/2010 | CA2740440A1 Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis |
| 04/22/2010 | CA2740134A1 Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| 04/22/2010 | CA2739557A1 Pharmaceutical product for up-dosing of allergy vaccine |
| 04/22/2010 | CA2739551A1 Dengue virus neutralizing antibodies and uses thereof |
| 04/22/2010 | CA2739469A1 Torque teno virus (ttv) isolates and compositions |
| 04/22/2010 | CA2739429A1 Immunoglobulin variants and uses thereof |
| 04/22/2010 | CA2739288A1 Immunoenhancer-linked oligomeric hiv vaccines |
| 04/22/2010 | CA2737352A1 Combination adjuvant formulation |
| 04/22/2010 | CA2725383A1 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 04/21/2010 | EP2177537A2 Antibodies to MAdCAM |
| 04/21/2010 | EP2177536A1 Antibodies against amyloid-beta peptide |
| 04/21/2010 | EP2177535A1 Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof |
| 04/21/2010 | EP2177534A2 Heteroclitic analogs of class i epitopes |
| 04/21/2010 | EP2177531A2 Cell permeable peptide |
| 04/21/2010 | EP2177231A2 Use of goat serum for veterinary treatment |
| 04/21/2010 | EP2177230A1 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 04/21/2010 | EP2177229A2 Functional composition or food comprising whey protein, antibody derived from milk or antibody |
| 04/21/2010 | EP2177228A1 DNA vaccination for treatment of autoimmune disease |
| 04/21/2010 | EP2177218A1 Regenerative therapy |
| 04/21/2010 | EP2176427A1 Avian influenza chimeric vlps |
| 04/21/2010 | EP2176413A1 Immunology treatment for biofilms |
| 04/21/2010 | EP2176408A2 NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
| 04/21/2010 | EP2176296A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 04/21/2010 | EP2176295A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 04/21/2010 | EP2176294A1 Mdl-1 uses |
| 04/21/2010 | EP2175885A1 Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |